AI Article Synopsis
- Double-hit lymphoma (DHL) is an aggressive type of B-cell lymphoma characterized by rearrangements of the MYC and BCL-2/BCL-6 genes, leading to a poor patient prognosis.
- The most crucial diagnostic tool for DHL is fluorescence in situ hybridization (FISH), but there is still no established standard treatment protocol.
- Emerging treatment strategies, such as targeted therapies, checkpoint inhibitors, and CAR T-cell therapy, are changing how DHL is approached clinically.
Article Abstract
Abstract Double-hit lymphoma (DHL) is a high-grade B-cell lymphoma with MYC and BCL-2/BCL-6 rearrangement, which is a invasive disease with a poor prognosis. FISH is the most important diagnostic method. There is no standard protocol for this disease yet. New therapeutic approaches including targeted therapy，checkpoint inhibitors and chimeric antigen receptor T-cell therapy are changing the paradigm of treatment for DHL. This review summarizes new developments in diagnosis and treatment of double-hit lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.04.052 | DOI Listing |
Publication Analysis
Top Keywords
[advances diagnosis
4
diagnosis therapy
4
therapy double-hit
4
double-hit lymphoma--review]
4
lymphoma--review] abstract double-hit
4
abstract double-hit lymphoma
4
lymphoma dhl
4
dhl high-grade
4
high-grade b-cell
4
b-cell lymphoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!